Sanofi India has strongly refuted a recent report claiming the company has initiated the sale or licensing of its flagship insulin brand, Lantus. In a stock exchange filing, Sanofi India said ...

At GoodRx, we saw an opportunity to contribute to the solution by partnering with Sanofi in 2023 to offer their most prescribed insulin, Lantus, for only $35 to all Americans—whether they had ...

That was the case for Lorena Sarmiento, another patient at Erie Health who uses Lantus, an insulin pen. Last fall, after the 340B discount changed, she was quoted $490 at her pharmacy — the ...

French drugmaker Sanofi will invest 1.3 billion euros ($1.40 billion) in a new insulin production facility at its existing site in Frankfurt, where it makes insulin brand Lantus, the company said ...

The company suggested that patients switch to other basal insulin options, including but not limited to Basaglar, Insulin Degludec, Insulin Glargine U-300, Lantus, Rezvoglar, Semglee, Toujeo and ...

Before insulin’s discovery in 1921, people with diabetes didn’t live long. A 14-year-old boy dying from diabetes was the first to receive an injection of insulin in 1922.

Sanofi announced last year that it was joining other drug companies to set a cap on insulin at $35. The new pricing went into effect on Jan. 1, CNN reported. Sanofi makes Lantus and had already ...

Sanofi makes Lantus and had already set the cost at $35 for uninsured patients. ... Eli Lilly cut the price of Humalog, the company’s most prescribed insulin, and Humulin by 70% in 2023.

GoodRx, a resource for healthcare savings and information, is working with Sanofi, a company that specializes in diabetes care, to offer people living with diabetes access to Lantus (insulin ...